Oxford BioMedica PLC
Medawar Centre<br>Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA
United Kingdom
Tel: 01865-783000
Fax: 01865-783001
Website: http://www.oxfordbiomedica.co.uk/
168 articles about Oxford BioMedica PLC
-
Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform
9/20/2023
Kyverna Therapeutics today announced a non-exclusive, multi-year license and supply agreement with Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"), a quality and innovation-led viral vector Contract and Development Manufacturing Organization (CDMO), enabling the use of LentiVector® with any Kyverna product.
-
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
9/20/2023
Oxford Biomedica plc announces interim results for the six months ended 30 June 2023.
-
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
9/20/2023
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
-
Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook
7/18/2023
Oxford Biomedica, a quality and innovation-led viral vector CDMO, has implemented Sapio's Electronic Laboratory Notebook as part of its digital transformation.
-
Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
5/15/2023
Oxford Biomedica plc, a quality and innovation-led viral vector CDMO, announces the launch of its 4th generation lentiviral vector delivery system, TetraVectaTM.
-
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
4/26/2023
Oxford Biomedica plc (LSE:OXB) today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director.
-
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
2/20/2023
Oxford Biomedica, a leading gene and cell therapy group, announces that Dr Frank Mathias will officially join Oxford Biomedica as Chief Executive Officer and Board member on Monday, 27th March 2023.
-
Oxford Biomedica Solutions forms new partnerships with three biotechnology companies
12/14/2022
Oxford Biomedica Solutions LLC, an AAV manufacturing and innovation company, announced that it has signed agreements with three additional U.S. based, biotechnology companies.
-
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
11/22/2022
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces the appointment of Dr Frank Mathias as Chief Executive Officer (CEO) and Board Director, effective March 2023.
-
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million
11/14/2022
Oxford, UK – 14November 2022: Oxford Biomedica plc, a leading gene and cell therapy group, announces exchange of contracts for the sale of its Windrush Court facility to Kadans Science Partner for £60 million.
-
Oxford Biomedica Solutions to Present Company Capabilities & Its Platform at Cell & Gene Meeting on the Mesa and European Society of Gene & Cell Therapy
10/5/2022
Oxford Biomedica Solutions LLC, an Oxford Biomedica company that offers an end-to-end, full solution platform approach to the development and production of Adeno-Associated Virus (AAV) vectors used in gene therapy, will be presenting a Company overview and providing updates on its industry leading capabilities at upcoming Industry conferences.
-
Oxford Biomedica plc Interim Results for the Six Months Ended 30 June 2022
9/15/2022
Oxford Biomedica plc, a leading gene and cell therapy group, announces interim results for the six months ended 30 June 2022.
-
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy
7/26/2022
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with an undisclosed US-based private biotechnology company advancing a new generation of adoptive cell therapies.
-
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology
7/26/2022
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology.
-
Companies are still developing and refining treatments and preventions for COVID-19, but not all of them are approved or authorized. Here’s a look at the latest COVID-19 news.
-
Oxford Biomedica Preliminary Results - Apr 20, 2022
4/20/2022
Oxford Biomedica plc, a leading cell and gene therapy group, announces its preliminary results for the year ended 31 December 2021.
-
Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology
3/11/2022
Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the “Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with Homology Medicines Inc.
-
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
3/10/2022
Homology Medicines, Inc., a genetic medicines company, announced the successful closing of the deal with Oxford Biomedica plc to establish an Adeno-Associated Virus Manufacturing and Innovation Business.
-
The FDA asked Homology Medicines to modify the pheNIX gene therapy trial's risk mitigation measures to prevent any serious issues that may arise.
-
Oxford Biomedica announces update to agreement with Sio Gene Therapies
1/31/2022
Oxford Biomedica plc announced today that it was informed on Monday 31 January by Sio Gene Therapies (Sio) that Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease.